Medarex competitive analysis

Explore Medarex's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 1, 2026
Patent NumberPublication DateTitleTotal Oppositions
Feb 27, 2019Human Monoclonal Antibodies To Programmed Death 1(Pd-1) And Methods For Treating Cancer Using Anti-Pd-1 Antibodies Alone Or In Combination With Other Immunotherapeutics2
Aug 16, 2017Methods For Enhanced Protein Production2
Jul 13, 2016Cation Exchange Chromatography2
Jun 10, 2015Transgenic Animals Expressing Chimeric Antibodies For Use In Preparing Human Antibodies2

Latest PTAB cases involving Medarex

Discover the latest PTAB cases involving Medarex, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Medarex with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 1, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
MEDAREX - 8 - -
DF MP DORRIES FRANK MOLNIA & POHLMAN PATENTANWALTE RECHTSANWALTE PARG MBB14 - - -
DF MP DRRIES FRANK MOLNIA & POHLMAN13 - - -
F HOFFMANN LA ROCHE34237 - -